1. Market Research
  2. > Healthcare Market Trends
  3. > Mice Model Market by Type, Technology, Disease, Service & Care Products - Analysis & Global Forecast to 2020

Mice models are indispensable tools in research activities with their capability to elucidate human disease processes, due to striking similarities between the anatomy, physiology, and genetics of humans and mice.

These advantages promote scientific discovery, understanding of the functions of individual genes, mechanisms of different diseases, and the effectiveness and toxicities of various drug molecules. Mice models are the most popularly used animal models due to their small size, short generation time, accelerated lifespan, low cost, and requirement of less space. These factors help in accelerating the research and development of drug therapies.

Ongoing innovations in mice models, personalized medicine fuelling the demand for personalized humanized mice models, continuous support in the form of investments and grants, and increase in R&D activities of pharmaceutical industries are some of the factors that are expected to drive the growth of the global mice model market in the coming years.

Market players are continuously focusing on innovations in mice models for research on various human diseases. Growing innovations and advances in mice models are providing increased options to researchers to conduct research activities in particular diseases, which is a major factor driving market growth.

On the other hand, factors like advancements in genetic techniques for the development of genetically modified rats have led to the increased usage of rat models, thereby restraining the mice model market to some extent. In addition, advances in zebrafish model development, increased benefits from cryopreservation, regulations & laws for the ethical use of animals, and alternative methods to animal testing are some factors expected to restrain the growth of the market. Moreover, the continuous need for improved mice models is posing as a major challenge for the global mice model market.

In 2015, the inbred mice are estimated to account for the largest share of the global mice model market, by type while genetically engineered mice models are expected to be the fastest-growing market segment, owing to high investments in the development of new and innovative knockout models that also increases the application areas for the models.

In 2015, North America is expected to account for the largest share of the global mice model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America’s large share is attributed to the revised funding plans by NIH to enhance the reproducibility of results, rising demands for monoclonal antibody production, continued and responsible use of animals ensured by animal care organizations, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

The major players in the market are focusing on various strategies (agreements, partnerships, joint ventures, collaborations, geographic expansion, new product launches, funds/grants, licensing, patents, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the models and services offered by top players in the mice model market. The report analyzes the mice model market, by type, technology, disease, service, and mice care products.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the mice model market
- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for mice models & services across regions
- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the mice model market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the mice model market

Table Of Contents

Mice Model Market by Type, Technology, Disease, Service and Care Products - Analysis and Global Forecast to 2020
TABLE OF CONTENTS

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY 24
1.5 LIMITATIONS 24
1.6 STAKEHOLDERS 24
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH METHODOLOGY STEPS 25
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 26
2.2.1 SECONDARY RESEARCH 26
2.2.1.1 Key data from secondary sources 26
2.2.2 PRIMARY RESEARCH 27
2.2.2.1 Key industry insights 28
2.2.2.2 Key data from primary sources 29
2.2.2.3 Key insights from primary sources 30
2.3 MARKET SIZE ESTIMATION METHODOLOGY 30
2.4 MARKET FORECAST METHODOLOGY 32
2.5 MARKET DATA VALIDATION AND TRIANGULATION 33
2.6 ASSUMPTIONS 33
3 EXECUTIVE SUMMARY 34
3.1 INTRODUCTION 34
3.2 CURRENT SCENARIO 34
3.3 FUTURE OUTLOOK 36
3.4 CONCLUSION 38
4 PREMIUM INSIGHTS 39
4.1 GLOBAL MICE MODEL MARKET 39
4.2 GEOGRAPHIC ANALYSIS: MICE CARE PRODUCTS MARKET, BY TYPE 40
4.3 MICE MODEL MARKET, BY TECHNOLOGY (2015 VS. 2020) 42

5 MARKET OVERVIEW 43
5.1 INTRODUCTION 44
5.2 MARKET SEGMENTATION 45
5.3 MARKET DYNAMICS 46
5.3.1 DRIVERS 46
5.3.1.1 Ongoing innovations in mice models 46
5.3.1.1.1 Mice models for immune diseases 46
5.3.1.1.2 Mice models for cancer 47
5.3.1.1.3 Mice models for rare diseases 47
5.3.1.2 Personalized medicine to fuel the demand for personalized humanized mice models 47
5.3.1.3 Continuous support in the form of grants and investments 48
5.3.1.4 Increase in RandD activities of pharmaceutical industries 49
5.3.1.5 Increasing focus of associations on the development of embryonic stem (ES) cells as well as knockout and mutant mice 49
5.3.1.5.1 International Mouse Phenotyping Consortium (IMPC) 49
5.3.1.5.2 International Knockout Mouse Consortium (IKMC) 49
5.3.2 RESTRAINTS 50
5.3.2.1 Increased usage of rat models 50
5.3.2.2 Advances in zebrafish model development 51
5.3.2.3 Increased benefits from cryopreservation 51
5.3.2.4 Regulations and laws for ethical use of animals in research 51
5.3.2.4.1 The Animal Welfare Act (AWA) 52
5.3.2.4.2 Public Health Service Policy (PHS)on Humane Care and Use of Laboratory Animals 52
5.3.2.5 Alternative methods to animal testing 52
5.3.3 OPPORTUNITIES 53
5.3.3.1 Rising demand of humanized mice models 53
5.3.3.2 Increase in monoclonal antibody production 53
5.3.4 CHALLENGE 54
5.3.4.1 Need for improved mice models 54
6 MICE MODEL MARKET, BY TYPE 55
6.1 INTRODUCTION 56
6.2 INBRED MICE 57
6.3 OUTBRED MICE 59
6.4 GENETICALLY ENGINEERED (KNOCKOUT and KNOCKIN) MICE 60
6.5 HYBRID/CONGENIC MICE 62
6.6 CONDITIONED/SURGICALLY MODIFIED MICE 63
6.7 SPONTANEOUS MUTANT MICE 64

7 MICE MODEL MARKET, BY TECHNOLOGY 65
7.1 INTRODUCTION 66
7.2 MICROINJECTION 68
7.3 EMBRYONIC STEM CELL INJECTION 69
7.4 NUCLEAR TRANSFERASE 70
7.5 OTHER TECHNOLOGIES 71
7.5.1 GENETICALLY MODIFIED SPERM-MEDIATED GENE TRANSFER 71
7.5.2 VIRUS/VECTOR-MEDIATED GENE TRANSFER 71
7.5.3 LIPOSOME-MEDIATED DNA AND ELECTROPORATION OF DNA 71
7.5.4 BIOLISTICS 71
7.5.5 CRISPR/CAS9, TALENS, AND ZFNS 72
8 MICE MODEL MARKET, BY SERVICE 74
8.1 INTRODUCTION 75
8.2 BREEDING SERVICES 77
8.3 CRYOPRESERVATION SERVICES 78
8.4 QUARANTINE SERVICES 79
8.5 REDERIVATION SERVICES 80
8.6 MODEL IN-LICENSING SERVICES 81
8.7 GENETIC TESTING SERVICES 82
8.8 OTHER SERVICES 83
9 MICE MODEL MARKET, BY DISEASE 85
9.1 INTRODUCTION 86
9.2 ONCOLOGY MICE MODELS 88
9.2.1 CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES 89
9.2.2 AGREEMENTS/COLLABORATIONS TO STRENGTHEN CANCER RESEARCH 89
9.2.3 INTRODUCTION OF NEW MICE MODELS FOR SPECIFIC CANCERS 89
9.2.4 EXPANSIONS TO SUPPORT CANCER RESEARCH FACILITIES 90
9.3 MICE MODELS FOR IMMUNOLOGY AND INFLAMMATION STUDIES 91
9.4 MICE MODELS FOR DIABETES STUDIES 93
9.5 MICE MODELS FOR CARDIOVASCULAR STUDIES 94
9.6 MICE MODELS FOR CENTRAL NERVOUS SYSTEM (CNS) STUDIES 95
9.7 MICE MODELS FOR METABOLISM AND REGULATION STUDIES 97
9.8 MICE MODELS FOR OTHER DISEASE STUDIES 98

10 MICE CARE PRODUCTS MARKET, BY TYPE 99
10.1 INTRODUCTION 100
10.2 CAGES 102
10.3 FEED 103
10.4 BEDDING 104
10.5 OTHERS 105
11 MICE MODEL MARKET, BY REGION 106
11.1 INTRODUCTION 107
11.2 NORTH AMERICA 109
11.2.1 U.S. 113
11.2.1.1 Revised funding plans by the NIH to enhance reproducibility of results 113
11.2.1.2 Growing biomedical research in the U.S. 113
11.2.1.3 Monoclonal antibody production to augment the use of mice models 115
11.2.1.4 Continued and responsible use of animals ensured by Animal Care Organizations 115
11.2.1.5 Development of biosimilars boosting the demand for preclinical services 116
11.2.1.6 Preclinical activities by CROs and pharmaceutical RandD 117
11.2.1.7 Partnerships between CROs and pharmaceutical companies 117
11.2.2 CANADA 120
11.2.2.1 Growing stem cell research activities in Canada 120
11.3 EUROPE 123
11.3.1 GERMANY 127
11.3.1.1 Launch of Pro-Test Deutschland 127
11.3.1.2 Flourishing biotechnology industry 127
11.3.2 U.K. 130
11.3.2.1 Investors demand strong statistics for animal studies in the U.K. 130
11.3.2.2 Increase in cell therapy preclinical research 130
11.3.3 FRANCE 133
11.3.3.1 Funding for rare disease projects in France 133
11.3.4 REST OF EUROPE (ROE) 135
11.3.4.1 Improving biomedical industry in Russia 135
11.3.4.2 Growth in biosimilars market calls for increased preclinical activities 136
11.3.4.3 Focus on rare disease research projects 137
11.3.4.4 Events conducted by animal care associations to promote the ethical use of mice 137
11.3.4.5 Increase in tailored mice models for diseases like cancer 138
11.4 ASIA-PACIFIC 141
11.4.1 CHINA 145
11.4.1.1 International alliances for RandD activities in China 145
11.4.1.2 Growing foray of pharmaceutical and mice model suppliers in China 145
11.4.1.3 Increasing investments from government and private sectors in China's life sciences sector 147
11.4.1.4 Initiatives to reduce longer approval times 148
11.4.1.5 Mandatory animal testing for all pharmaceutical drugs and cosmetics in China 149
11.4.1.6 Intellectual property (IP) breaches, a challenge for the Chinese market 149
11.4.2 JAPAN 152
11.4.2.1 Growth in biomedical and medical research in Japan 152
11.4.2.2 Research into regenerative medicines 153
11.4.3 INDIA 155
11.4.3.1 Growing presence of global players 155
11.4.3.2 Development of bioclusters to boost India's biotechnology industry 155
11.4.3.3 RandD activities by Indian pharmaceutical companies to boost preclinical research 156
11.4.3.4 Likely shift of outsourcing preclinical activities from India towards European nations 157
11.4.3.5 Limited infrastructural facilities in India, a major hindrance to the mice model market 157
11.4.3.6 Weak intellectual property environment in India 158
11.4.4 REST OF ASIA-PACIFIC (ROAPAC) 160
11.4.4.1 Influx of international players 160
11.4.4.2 Ongoing biomedical research activities in Australia to strengthen the market 162
11.4.4.3 Growth in translational and biomedical research in Singapore 162
11.4.4.4 Increase in animal research in Malaysia 163
11.4.4.5 Rising pharmaceutical and biotechnology RandD activities in Korea 164
11.5 REST OF WORLD (ROW) 167
11.5.1.1 Pharmaceutical, biotechnology, and research industries in Brazil to bolster the market 168
11.5.1.2 Favorable business environment for pharmaceutical and biotechnology industries in Saudi Arabia and the UAE 168
12 COMPETITIVE LANDSCAPE 172
12.1 OVERVIEW 172
12.2 MICE MODEL MARKET: MARKET SHARE ANALYSIS (2014) 173
12.2.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 174
12.2.2 THE JACKSON LABORATORY 175
12.2.3 TACONIC BIOSCIENCES, INC. 176
12.2.4 HARLAN LABORATORIES, INC. (ENVIGO) 177
12.3 COMPETITIVE SITUATION AND TRENDS 179
12.3.1 COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES PARTNERSHIPS, AND JOINT VENTURES 180
12.3.2 GRANTS and FUNDS 181
12.3.3 LICENSING 182
12.3.4 NEW PRODUCT LAUNCHES 183
12.3.5 EXPANSIONS 185
12.3.6 PATENTS 186
12.3.7 ACQUISITIONS 187
12.3.8 OTHERS 188
13 COMPANY PROFILES 190
(Overview, Financials, Products and Services, Strategy, and Developments)*
13.1 INTRODUCTION 190
13.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 191
13.3 THE JACKSON LABORATORY 196
13.4 TACONIC BIOSCIENCES, INC. 202
13.5 ENVIGO 208
13.6 COVANCE, INC. 213
13.7 JANVIER LABS 216
13.8 HARBOUR ANTIBODIES BV 218
13.9 TRANSGENIC, INC. 219
13.10 GENOWAY SA 223
13.11 SAGE LABS, INC. (A SUBSIDIARY OF HORIZON DISCOVERY GROUP PLC) 226
13.12 INGENIOUS TARGETING LABORATORY 229
*Details on Financials, Product and Services, Strategy, and Developments might not be captured in case of unlisted companies.
14 APPENDIX 231
14.1 DISCUSSION GUIDE 231
14.2 COMPANY DEVELOPMENTS (2012-2015) 237
14.2.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 237
14.2.2 THE JACKSON LABORATORY (JAX) 237
14.2.3 TACONIC BIOSCIENCES INC. 239
14.2.4 ENVIGO 241
14.2.5 COVANCE, INC. 242
14.2.6 TRANSGENIC, INC. 243
14.2.7 GENOWAY SA 245
14.2.8 SAGE LABS, INC. 245
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 247
14.4 AVAILABLE CUSTOMIZATIONS 247
14.5 RELATED REPORTS 248
LIST OF TABLES

TABLE 1 ONGOING INNOVATIONS IN MICE MODELS ARE PROPELLING THE GROWTH OF GLOBAL MICE MODEL MARKET 50
TABLE 2 INCREASED USAGE OF RAT MODELS IS LIMITING THE ADOPTION OF MICE MODELS IN RESEARCH 53
TABLE 3 INCREASE IN MONOCLONAL ANTIBODY PRODUCTION USING MICE MODELS HAS A HUGE POTENTIAL FOR THE MICE MODEL MARKET 54
TABLE 4 NEED FOR IMPROVED MICE MODELS IS A MAJOR MARKET CHALLENGE 54
TABLE 5 MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 57
TABLE 6 INBRED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 58
TABLE 7 OUTBRED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 59
TABLE 8 GENETICALLY ENGINEERED MICE MODEL MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 61
TABLE 9 HYBRID/CONGENIC MICE MODEL MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 62
TABLE 10 CONDITIONED/SURGICALLY MODIFIED MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 63
TABLE 11 SPONTANEOUS MUTANT MICE MODEL MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 64
TABLE 12 MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION) 67
TABLE 13 MICROINJECTION MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 68
TABLE 14 EMBRYONIC STEM CELL INJECTION MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 69
TABLE 15 NUCLEAR TRANSFERASE MARKET SIZE, BY COUNTRY,
2013-2020 (USD THOUSAND) 70
TABLE 16 OTHER MICE MODEL TECHNOLOGIES MARKET SIZE, BY COUNTRY,
2013-2020 (USD THOUSAND) 73
TABLE 17 GLOBAL MICE MODEL MARKET, BY SERVICE, 2013-2020 (USD MILLION) 76
TABLE 18 MICE MODEL MARKET SIZE FOR BREEDING SERVICES, BY COUNTRY,
2013-2020 (USD MILLION) 77
TABLE 19 MICE MODEL MARKET SIZE FOR CRYOPRESERVATION SERVICES,
BY COUNTRY, 2013-2020 (USD MILLION) 78
TABLE 20 MICE MODEL MARKET SIZE FOR QUARANTINE SERVICES, BY COUNTRY,
2013-2020 (USD MILLION) 79
TABLE 21 MICE MODEL MARKET SIZE FOR REDERIVATION SERVICES, BY COUNTRY,
2013-2020 (USD MILLION) 80
TABLE 22 MICE MODEL MARKET SIZE FOR MODEL IN-LICENSING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION) 81
TABLE 23 MICE MODEL MARKET SIZE FOR GENETIC TESTING SERVICES, BY COUNTRY, 2013-2020 (USD MILLION) 82
TABLE 24 MICE MODEL MARKET SIZE FOR OTHER SERVICES, BY COUNTRY,
2013-2020 (USD MILLION) 84
TABLE 25 GLOBAL MICE MODEL MARKET, BY DISEASE, 2013-2020 (USD MILLION) 87
TABLE 26 RECENT CANCER RESEARCH STUDIES USING MICE MODELS 88
TABLE 27 ONCOLOGY MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 90
TABLE 28 MICE MODEL MARKET FOR IMMUNOLOGY AND INFLAMMATION STUDIES,
BY COUNTRY, 2013-2020 (USD MILLION) 92
TABLE 29 MICE MODELS MARKET FOR DIABETES STUDIES, BY COUNTRY,
2013-2020 (USD MILLION) 93
TABLE 30 MICE MODELS MARKET FOR CARDIOVASCULAR STUDIES, BY COUNTRY,
2013-2020 (USD MILLION) 94
TABLE 31 RECENT CNS DISORDER-RELATED RESEARCH STUDIES USING MICE MODELS 95
TABLE 32 MICE MODEL MARKET FOR CENTRAL NERVOUS SYSTEM STUDIES,
BY COUNTRY, 2013-2020 (USD MILLION) 96
TABLE 33 MICE MODEL MARKET FOR METABOLISM AND REGULATION STUDIES,
BY COUNTRY, 2013-2020 (USD MILLION) 97
TABLE 34 MICE MODEL MARKET FOR OTHER DISEASE STUDIES, BY COUNTRY,
2013-2020 (USD MILLION) 98
TABLE 35 GLOBAL MICE CARE PRODUCTS MARKET SIZE, BY TYPE,
2013-2020 (USD MILLION) 101
TABLE 36 MICE CARE PRODUCTS MARKET SIZE FOR CAGES, BY REGION,
2013-2020 (USD THOUSAND) 102
TABLE 37 MICE CARE PRODUCTS MARKET SIZE FOR FEED, BY REGION,
2013-2020 (USD THOUSAND) 103
TABLE 38 MICE CARE PRODUCTS MARKET SIZE FOR BEDDING, BY REGION,
2013-2020 (USD THOUSAND) 104
TABLE 39 OTHER MICE CARE PRODUCTS MARKET SIZE, BY REGION,
2013-2020 (USD THOUSAND) 105
TABLE 40 MICE MODEL MARKET SIZE, BY REGION, 2013-2020 (USD MILLION) 107
TABLE 41 NORTH AMERICA: MICE MODEL MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 109
TABLE 42 NORTH AMERICA: MICE MODEL MARKET SIZE, BY TYPE,
2013-2020 (USD MILLION) 111
TABLE 43 NORTH AMERICA: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD MILLION) 111
TABLE 44 NORTH AMERICA: MICE MODEL MARKET SIZE, BY SERVICE,
2013-2020 (USD MILLION) 112
TABLE 45 NORTH AMERICA: MICE MODEL MARKET SIZE, BY DISEASE,
2013-2020 (USD MILLION) 112
TABLE 46 NORTH AMERICA: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD MILLION) 113
TABLE 47 NIH FUNDING FOR PROJECTS RELATED TO ANIMAL MODELS 114
TABLE 48 ASSOCIATIONS DIRECTLY RELATED TO THE ANIMAL MODEL MARKET 116
TABLE 49 ASSOCIATIONS INDIRECTLY RELATED TO THE ANIMAL MODEL MARKET 116
TABLE 50 U.S.: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 118
TABLE 51 U.S.: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION) 118
TABLE 52 U.S.: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION) 119
TABLE 53 U.S.: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 119
TABLE 54 CANADA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 120
TABLE 55 CANADA: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD MILLION) 121
TABLE 56 CANADA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION) 121
TABLE 57 CANADA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 122
TABLE 58 EUROPE: MICE MODEL MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 123
TABLE 59 EUROPE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 125
TABLE 60 EUROPE: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD MILLION) 125
TABLE 61 EUROPE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION) 126
TABLE 62 EUROPE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 126
TABLE 63 EUROPE: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND) 127
TABLE 64 GERMANY: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 128
TABLE 65 GERMANY: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD MILLION) 128
TABLE 66 GERMANY: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION) 129
TABLE 67 GERMANY: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 129
TABLE 68 U.K.: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 131
TABLE 69 U.K.: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION) 131
TABLE 70 U.K.: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION) 132
TABLE 71 U.K.: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 132
TABLE 72 FRANCE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 133
TABLE 73 FRANCE: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD THOUSAND) 134
TABLE 74 FRANCE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION) 134
TABLE 75 FRANCE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 135
TABLE 76 STAGES OF PHARMA 2020 STRATEGY 136
TABLE 77 EUROPEAN ANIMAL CARE ASSOCIATIONS AND THEIR EVENTS 137
TABLE 78 ROE: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 138
TABLE 79 ROE: MICE MODEL MARKET SIZE, BY TECHNOLOGY, 2013-2020 (USD MILLION) 139
TABLE 80 ROE: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD MILLION) 139
TABLE 81 ROE: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 140
TABLE 82 ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 141
TABLE 83 ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 143
TABLE 84 ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD THOUSAND) 143
TABLE 85 ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY SERVICE,
2013-2020 (USD MILLION) 144
TABLE 86 ASIA-PACIFIC: MICE MODEL MARKET SIZE, BY DISEASE,
2013-2020 (USD MILLION) 144
TABLE 87 ASIA-PACIFIC: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND) 145
TABLE 88 CHINA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 150
TABLE 89 CHINA: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD THOUSAND) 150
TABLE 90 CHINA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND) 151
TABLE 91 CHINA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 151
TABLE 92 JAPAN: SIGNIFICANT PARTNERSHIPS 152
TABLE 93 JAPAN: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 153
TABLE 94 JAPAN: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD THOUSAND) 154
TABLE 95 JAPAN: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND) 154
TABLE 96 JAPAN: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 155
TABLE 97 STUDY RESULTS REGARDING RandD EXPENDITURE OF 25 PHARMACEUTICAL COMPANIES 156
TABLE 98 INDIA: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 158
TABLE 99 INDIA: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD THOUSAND) 159
TABLE 100 INDIA: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND) 159
TABLE 101 INDIA: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD MILLION) 160
TABLE 102 ROAPAC: PLAYER ACTIVITY, 2013 TO 2015 160
TABLE 103 REST OF APAC: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 164
TABLE 104 REST OF APAC: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD THOUSAND) 165
TABLE 105 REST OF APAC: MICE MODEL MARKET SIZE, BY SERVICE,
2013-2020 (USD THOUSAND) 165
TABLE 106 REST OF APAC: MICE MODEL MARKET SIZE, BY DISEASE,
2013-2020 (USD MILLION) 166
TABLE 107 ROW: MICE MODEL MARKET SIZE, BY TYPE, 2013-2020 (USD THOUSAND) 169
TABLE 108 ROW: MICE MODEL MARKET SIZE, BY TECHNOLOGY,
2013-2020 (USD THOUSAND) 169
TABLE 109 ROW: MICE MODEL MARKET SIZE, BY SERVICE, 2013-2020 (USD THOUSAND) 170
TABLE 110 ROW: MICE MODEL MARKET SIZE, BY DISEASE, 2013-2020 (USD THOUSAND) 170
TABLE 111 ROW: MICE CARE PRODUCTS, BY TYPE, 2013-2020 (USD THOUSAND) 171
TABLE 112 COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS (2012-2015) 180
TABLE 113 GRANTS and FUNDS, 2012-2015 181
TABLE 114 LICENSING (2012-2015) 182
TABLE 115 NEW PRODUCT LAUNCHES (2012-2015) 184
TABLE 116 KEY PLAYERS FOCUSING ON EXPANSIONS (2012-2015) 185
TABLE 117 PATENTS (2012-2015) 186
TABLE 118 ACQUISITIONS (2012-2015) 187
TABLE 119 KEY PLAYERS FOCUSING ON OTHER STRATEGIES (2012-2015) 189
LIST OF FIGURES

FIGURE 1 GLOBAL MICE MODEL MARKET: RESEARCH METHODOLOGY STEPS 25
FIGURE 2 SAMPLING FRAME: PRIMARY RESEARCH 28
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 29
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 31
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 31
FIGURE 6 RESEARCH DESIGN 32
FIGURE 7 DATA TRIANGULATION METHODOLOGY 33
FIGURE 8 NORTH AMERICA DOMINATES THE GLOBAL MICE MODEL MARKET 35
FIGURE 9 CRYOPRESERVATION SERVICES MARKET TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020 37
FIGURE 10 ASIA-PACIFIC IS EXPECTED TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 38
FIGURE 11 ONGOING INNOVATIONS IN MICE MODELS TO SPUR MARKET GROWTH DURING THE FORECAST PERIOD 39
FIGURE 12 NORTH AMERICA DOMINATED THE MICE CARE PRODUCTS MARKET IN 2015 40
FIGURE 13 ASIA-PACIFIC MARKET TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 41
FIGURE 14 MICROINJECTION TECHNOLOGY COMMANDED THE LARGEST SHARE IN 2015 42
FIGURE 15 GLOBAL MICE MODEL MARKET SEGMENTATION 45
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
FIGURE 17 GENETICALLY ENGINEERED MICE TO BE THE FASTEST GROWING SEGMENT 56
FIGURE 18 MICROINJECTION TECHNOLOGY COMMANDED THE LARGEST SHARE OF MICE MODEL MARKET IN 2015 66
FIGURE 19 MICE MODEL MARKET, BY SERVICE 75
FIGURE 20 BREEDING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE MICE MODEL MARKET IN 2015 76
FIGURE 21 MICE MODEL MARKET, BY DISEASE 86
FIGURE 22 ONCOLOGY MICE MODELS TO DOMINATE THE MICE MODEL MARKET IN 2015 87
FIGURE 23 MICE CARE PRODUCTS MARKET, BY TYPE 100
FIGURE 24 CAGES ACCOUNTED FOR THE LARGEST SHARE OF THE MICE CARE PRODUCTS MARKET IN 2015 101
FIGURE 25 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR IN THE MICE MODEL MARKET DURING THE FORECAST PERIOD 108
FIGURE 26 THE U.S. COMMANDED THE LARGEST SHARE IN THE MICE MODEL MARKET IN NORTH AMERICA IN 2015 110
FIGURE 27 GERMANY DOMINATED THE EUROPEAN MICE MODEL MARKET IN 2015 124
FIGURE 28 NUMBER OF CELL THERAPY PRECLINICAL STUDIES LISTED IN THE PRECLINICAL RESEARCH DATABASE IN THE U.K., 2013-2015 130
FIGURE 29 CHINA: THE FASTEST GROWING COUNTRY IN THE ASIA-PACIFIC MICE MODEL MARKET 142
FIGURE 30 CHINA PHARMA PARTNERING ACTIVITY BY STAGE - 2009-2014 147
FIGURE 31 ONCOLOGY MICE MODELS TO DOMINATE THE ROW MICE MODELS MARKET,
BY DISEASES 167
FIGURE 32 MAJOR PLAYERS FOCUSED ON INORGANIC GROWTH STRATEGIES 172
FIGURE 33 MICE MODEL MARKET SHARE, BY KEY PLAYER, 2014 173
FIGURE 34 BATTLE FOR MARKET SHARE: MAJOR COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS FORMED THE KEY STRATEGY (2012-2015) 179
FIGURE 35 KEY PLAYERS FOCUSING ON COLLABORATIONS, AGREEMENTS, STRATEGIC ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS (2012-2015) 180
FIGURE 36 KEY PLAYERS FOCUSING ON GRANTS and FUNDS (2012-2015) 181
FIGURE 37 KEY PLAYERS FOCUSING ON LICENSING (2012-2015) 182
FIGURE 38 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCHES (2012-2015) 183
FIGURE 39 KEY PLAYERS FOCUSING ON EXPANSIONS (2012-2015) 185
FIGURE 40 KEY PLAYERS FOCUSING ON PATENTS (2012-2015) 186
FIGURE 41 KEY PLAYERS FOCUSING ON ACQUISITIONS (2012-2015) 187
FIGURE 42 KEY PLAYERS FOCUSING ON OTHER STRATEGIES (2012-2015) 188
FIGURE 43 BUSINESS FOCUS OF TOP MARKET PLAYERS 190
FIGURE 44 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT 191
FIGURE 45 THE JACKSON LABORATORY: COMPANY SNAPSHOT 196
FIGURE 46 COVANCE, INC.: COMPANY SNAPSHOT 213
FIGURE 47 GENOWAY SA: COMPANY SNAPSHOT 223

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Immune Checkpoint Drugs in Oncology: Analytical Tool

Immune Checkpoint Drugs in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.